Page 1459 - Hematology_ Basic Principles and Practice ( PDFDrive )

1297.e2 Part VII Hematologic Malignancies

39. van Oers MH, Klasa R, Marcus RE, et al: Rituximab maintenance as front-line treatment for patients with follicular lymphoma. J Clin
improves clinical outcome of relapsed/resistant follicular non-Hodgkin Oncol 22:2654, 2004.
lymphoma in patients both with and without rituximab during induc- 58. Rummel MJ, Al-Batran SE, Kim SZ, et al: Bendamustine plus ritux-
tion: results of a prospective randomized phase 3 intergroup trial. Blood imab is effective and has a favorable toxicity profile in the treatment
108:3295, 2006. of mantle cell and low-grade non-Hodgkin’s lymphoma. J Clin Oncol
40. Forstpointner R, Unterhalt M, Dreyling M, et al: Maintenance therapy 23:3383, 2005.
with rituximab leads to a significant prolongation of response duration 59. Cheson BD, Friedberg JW, Kahl BS, et al: Bendamustine produces
after salvage therapy with a combination of rituximab, fludarabine, durable responses with an acceptable safety profile in patients with
cyclophosphamide, and mitoxantrone (R-FCM) in patients with recur- rituximab-refractory indolent non-Hodgkin lymphoma. Clin Lym-
ring and refractory follicular and mantle cell lymphomas: Results of a phoma Myeloma Leuk 10:452, 2010.
prospective randomized study of the German Low Grade Lymphoma 60. Smalley RV, Weller E, Hawkins MJ, et al: Final analysis of the ECOG
Study Group (GLSG). Blood 108:4003, 2006. I-COPA trial (E6484) in patients with non-Hodgkin’s lymphoma
41. Hainsworth JD, Litchy S, Shaffer DW, et al: Maximizing therapeutic treated with interferon alfa (IFN-alpha2a) plus an anthracycline-based
benefit of rituximab: maintenance therapy versus re-treatment at induction regimen. Leukemia 15:1118, 2001.
progression in patients with indolent non-Hodgkin’s lymphoma–a ran- 61. Smalley RV, Andersen JW, Hawkins MJ, et al: Interferon alfa com-
domized phase II trial of the Minnie Pearl Cancer Research Network. J bined with cytotoxic chemotherapy for patients with non-Hodgkin’s
Clin Oncol 23:1088, 2005. lymphoma. N Engl J Med 327:1336, 1992.
42. Friedberg JW, Taylor MD, Cerhan JR, et al: Follicular lymphoma in 62. Rohatiner AZ, Gregory WM, Peterson B, et al: Meta-analysis to evalu-
the United States: first report of the national LymphoCare study. J Clin ate the role of interferon in follicular lymphoma. J Clin Oncol 23:2215,
Oncol 27:1202, 2009. 2005.
43. Ketterer N, Salles G, Moullet I, et al: Factors associated with successful 63. Fisher RI, Dana BW, LeBlanc M, et al: Interferon alpha consolidation
mobilization of peripheral blood progenitor cells in 200 patients with after intensive chemotherapy does not prolong the progression-free
lymphoid malignancies. Br J Haematol 103:235, 1998. survival of patients with low-grade non-Hodgkin’s lymphoma: results
44. Rummel MJ, Niederle N, Maschmeyer G, et al: Bendamustine plus of the Southwest Oncology Group randomized phase III study 8809.
rituximab versus CHOP plus rituximab as first-line treatment for patients J Clin Oncol 18:2010, 2000.
with indolent and mantle-cell lymphomas: an open-label, multicentre, 64. http://www.fda.gov/cder/foi/label/2006/103705s5230-s5231lbl.pdf.
randomised, phase 3 non-inferiority trial. Lancet 381:1203, 2013. 65. http://www.emea.eu.int/humandocs/Humans/EPAR/mabthera/
45. Rummel M, Kaiser U, Balser C, et al: Bendamustine plus rituximab mabthera.htm.
versus fludarabine plus rituximab for patients with relapsed indolent 66. Swenson WT, Wooldridge JE, Lynch CF, et al: Improved survival of fol-
and mantle-cell lymphomas: a multicentre, randomised, open-label, licular lymphoma patients in the United States. J Clin Oncol 23:5019,
non-inferiority phase 3 trial. Lancet Oncol 17:57, 2016. 2005.
46. Portlock CS, Rosenberg SA, Glatstein E, et al: (1976) Treatment of 67. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, et al: IDEC-C2B8: results
advanced non-Hodgkin’s lymphomas with favorable histologies: pre- of a phase I multiple-dose trial in patients with relapsed non-Hodgkin’s
liminary results of a prospective trial. Blood 47:747, 1976. lymphoma. J Clin Oncol 15:3266, 1997.
47. Gallagher CJ, Gregory WM, Jones AE, et al: Follicular lymphoma: 68. McLaughlin P, Grillo-Lopez AJ, Link BK, et al: Rituximab chimeric
prognostic factors for response and survival. J Clin Oncol 4:1470, 1986. anti-CD20 monoclonal antibody therapy for relapsed indolent lym-
48. Bagley CM, Jr, Devita VT, Jr, Berard CW, et al: Advanced lymphosar- phoma: half of patients respond to a four-dose treatment program. J
coma: intensive cyclical combination chemotherapy with cyclophos- Clin Oncol 16:2825, 1998.
phamide, vincristine, and prednisone. Ann Intern Med 76:227, 1972. 69. Davis TA, White CA, Grillo-Lopez AJ, et al: Single-agent monoclonal
49. Lister TA, Cullen MH, Beard ME, et al: Comparison of combined and antibody efficacy in bulky non-Hodgkin’s lymphoma: results of a phase
single-agent chemotherapy in non-Hodgkin’s lymphoma of favourable II trial of rituximab. J Clin Oncol 17:1851, 1999.
histological type. Br Med J 1:533, 1978. 70. McLaughlin P, Hagemeister FB, Grillo-Lopez AJ: Rituximab in indolent
50. Dana BW, Dahlberg S, Nathwani BN, et al: Long-term follow-up of lymphoma: the single-agent pivotal trial. Semin Oncol 26:79, 1999.
patients with low-grade malignant lymphomas treated with doxorubicin- 71. Colombat P, Salles G, Brousse N, et al: Rituximab (anti-CD20 mono-
based chemotherapy or chemoimmunotherapy. J Clin Oncol 11:644, clonal antibody) as single first-line therapy for patients with follicular
1993. lymphoma with a low tumor burden: clinical and molecular evaluation.
51. Peterson BA, Petroni GR, Frizzera G, et al: Prolonged single-agent Blood 97:101, 2001.
versus combination chemotherapy in indolent follicular lymphomas: a 72. Colombat P, Brousse N, Morschhauser F, et al: Single treatment with
study of the cancer and leukemia group B. J Clin Oncol 21:5, 2003. rituximab monotherapy for low-tumor burden follicular lymphoma
52. Al-Tourah AJG, Hoskins PJ, Klasa RJ, et al: The impact of initial (FL): survival analyses with extended follow-up of 7 years. Blood
treatment of advanced stage indolent lymphoma on the risk of trans- 108:147a, 2006.
formation. Proc ASCO 24:7510, 2006. 73. Piro LD, White CA, Grillo-Lopez AJ, et al: Extended Rituximab
53. Zinzani PL, Magagnoli M, Moretti L, et al: Randomized trial of (anti-CD20 monoclonal antibody) therapy for relapsed or refractory
fludarabine versus fludarabine and idarubicin as frontline treatment in low-grade or follicular non-Hodgkin’s lymphoma. Ann Oncol 10:655,
patients with indolent or mantle-cell lymphoma. J Clin Oncol 18:773, 1999.
2000. 74. Davis TA, Grillo-Lopez AJ, White CA, et al: Rituximab anti-CD20
54. Hagenbeek A, Eghbali H, Monfardini S, et al: Phase III intergroup monoclonal antibody therapy in non-Hodgkin’s lymphoma: safety and
study of fludarabine phosphate compared with cyclophosphamide, efficacy of re-treatment. J Clin Oncol 18:3135, 2000.
vincristine, and prednisone chemotherapy in newly diagnosed patients 75. Martinelli G, Schmitz SF, Utiger U, et al: Long-term follow-up of
with stage III and IV low-grade malignant Non-Hodgkin’s lymphoma. patients with follicular lymphoma receiving single-agent rituximab at
J Clin Oncol 24:1590, 2006. two different schedules in trial SAKK 35/98. J Clin Oncol 28:4480, 2010.
55. Hochster HS, Oken MM, Winter JN, et al: Phase I study of fludarabine 76. Salles G, Seymour JF, Offner F, et al: Rituximab maintenance for 2 years
plus cyclophosphamide in patients with previously untreated low-grade in patients with high tumour burden follicular lymphoma responding
lymphoma: results and long-term follow-up–a report from the Eastern to rituximab plus chemotherapy (PRIMA): a phase 3, randomised
Cooperative Oncology Group. J Clin Oncol 18:987, 2000. controlled trial. Lancet 377:42, 2011.
56. Velasquez WS, Lew D, Grogan TM, et al: Combination of fludarabine 77. Friedberg JW: Rituximab maintenance in follicular lymphoma: PRIMA.
and mitoxantrone in untreated stages III and IV low-grade lymphoma: Lancet 377:4, 2011.
S9501. J Clin Oncol 21:1996, 2003. 78. Czuczman MS, Koryzna A, Mohr A, et al: Rituximab in combination
57. Zinzani PL, Pulsoni A, Perrotti A, et al: Fludarabine plus mitoxantrone with fludarabine chemotherapy in low-grade or follicular lymphoma. J
with and without rituximab versus CHOP with and without rituximab Clin Oncol 23:694, 2005.